成都圣诺生物科技股份有限公司董事会提名委员会 关于提名公司第五届董事会非独立董事候选人的审查意见 余啸海 2025 年12月1 日 （本页无正文,为《成都圣诺生物科技股份有限公司董事会提名委员会关于提名 公司第五届董事会非独立董事候选人的审查意见》签字页) 根据《中华人民共和国公司法》（以下简称"《公司法》"）《上海证券交 易所科创板股票上市规则》等法规以及《成都圣诺生物科技股份有限公司章程》 等公司制度的规定，我们作为成都圣诺生物科技股份有限公司（以下简称"公司"） 第四届董事会提名委员会委员，本着对公司及全体股东负责的态度，基于审慎独 立判断的立场，认真审核了公司非独立董事候选人文永均先生、王晓莉女士、余 啸海先生、伍利先生、杨广林先生、曾德志先生的个人履历等相关资料，现就提 名文永均先生、王晓莉女士、余啸海先生、伍利先生、杨广林先生、曾德志先生 为公司第五届董事会非独立董事候选人事项发表审查意见如下： 公司第五届非独立董事会董事候选人文永均先生、王晓莉女士、余啸海先生、 伍利先生、杨广林先生、曾德志先生符合担任公司董事的任职条件，具备履行董 事职责的能力，不存在《公司法》《上海证券交易所科创板股票上市规 ...

独立董事提名人声明与承诺 提名人成都圣诺生物科技股份有限公司董事会,现提名徐正 松为成都圣诺生物科技股份有限公司第五届董事会独立董事候 选人,并已充分了解被提名人职业、学历、职称、详细的工作经 历、全部兼职、有无重大失信等不良记录等情况。被提名人已书 面同意出任成都圣诺生物科技股份有限公司第五届董事会独立 董事候选人(参见该独立董事候选人声明)。提名人认为,被提 名人具备独立董事任职资格,与成都圣诺生物科技股份有限公司 之间不存在任何影响其独立性的关系,具体声明并承诺如下: 一、被提名人具备上市公司运作的基本知识,熟悉相关法律、 行政法规、规章及其他规范性文件,具有五年以上法律、经济、 会计、财务、管理等履行独立董事职责所必需的工作经验。 被提名人已经参加培训并取得证券交易所认可的相关培训 证明材料。 二、被提名人任职资格符合下列法律、行政法规和部门规章 的要求: (一)《中华人民共和国公司法》等关于董事任职资格的规 定: (二)《中华人民共和国公务员法》关于公务员兼任职务的 规定; (三)中国证监会《上市公司独立董事管理办法》、上海证 拳交易所自律监管规则以及公司章程有关独立董事任职资格和 条件的相关规定; ...

根据《中华人民共和国公司法》（以下简称"《公司法》"）《上海证券交 易所科创板股票上市规则》《上市公司独立董事管理办法》等法规以及《成都圣 诺生物科技股份有限公司章程》《成都圣诺生物科技股份有限公司独立董事工作 制度》等公司制度的规定，我们作为成都圣诺生物科技股份有限公司（以下简称 "公司"）第四届董事会提名委员会委员，本着对公司及全体股东负责的态度， 基于审慎独立判断的立场，认真审核了公司独立董事候选人徐正松先生、刘霞女 士、贺泽凯先生的个人履历等相关资料，现就提名徐正松先生、刘霞女士、贺泽 凯先生为公司第五届董事会独立董事候选人事项发表审查意见如下： 截至目前，徐正松先生、刘霞女士、贺泽凯先生未直接或间接持有公司股票， 与公司控股股东、实际控制人、持有公司 5%以上股份的股东及其他董事、高级 管理人员之间不存在关联关系。徐正松先生、刘霞女士、贺泽凯先生不存在《公 司法》规定的不得担任公司董事、高级管理人员的情形，未受过中国证监会行政 处罚和证券交易所公开谴责或通报批评，没有因涉嫌犯罪被司法机关立案侦查或 者涉嫌违法违规被中国证监会立案调查等情形，亦不属于"失信被执行人"，符 合《公司法》《上海证券交易所科 ...

独立董事候选人声明与承诺 本人徐正松，已充分了解并同意由提名人成都圣诺生物科技 股份有限公司董事会提名为成都圣诺生物科技股份有限公司第 五届董事会独立董事候选人。本人公开声明，本人具备独立董事 任职资格，保证不存在任何影响本人担任成都圣诺生物科技股份 有限公司独立董事独立性的关系，具体声明并承诺如下： 一、本人具备上市公司运作的基本知识，熟悉相关法律、行 政法规、部门规章及其他规范性文件，具有五年以上法律、经济 会计、财务、管理等履行独立董事职责所必需的工作经验。 二、本人任职资格符合下列法律、行政法规和部门规章以及 公司规章的要求： （一）《中华人民共和国公司法》等关于董事任职资格的规 定； （二）《中华人民共和国公务员法》关于公务员兼任职务的 规定； （三）中国证监会《上市公司独立董事管理办法》和上海证 券交易所自律监管规则有关独立董事任职资格和条件的相关规 定； （四）中共中央纪委、中共中央组织部《关于规范中管干部 辞去公职或者退（离）休后担任上市公司、基金管理公司独立董 事、独立监事的通知》的规定； （五）中共中央组织部《关于进一步规范党政领导干部在企 业兼职（任职）问题的意见》的相关规定； －1－ ...

成都圣诺生物科技股份有限公司 关于董事会换届选举的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688117 证券简称：圣诺生物 公告编号：2025-035 成都圣诺生物科技股份有限公司（以下简称"公司"）第四届董事会任期即 将届满，根据《中华人民共和国公司法》《上海证券交易所科创板股票上市规则》 《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等法律、 法规、规范性文件以及《公司章程》等有关规定，公司开展了董事会换届选举工 作，现将本次董事会换届选举情况公告如下： 一、董事会换届选举情况 根据《公司法》《公司章程》等有关规定，公司董事会共 9 人，由 6 名非独 立董事和 3 名独立董事组成。公司于 2025 年 12 月 1 日召开了第四届董事会第二 十八次会议，审议通过了《关于公司董事会换届选举暨提名第五届董事会非独立 董事候选人的议案》《关于公司董事会换届选举暨提名第五届董事会独立董事候 选人的议案》。经公司董事会提名委员会对第五届董事会董事候选人的任职资格 审查，董事会同意提名 ...

证券代码：688117 证券简称：圣诺生物 公告编号：2025-036 成都圣诺生物科技股份有限公司 关于召开2025年第一次临时股东会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2025 年 12 月 17 日 至2025 年 12 月 17 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 重要内容提示： 一、 召开会议的基本情况 （一） 股东会类型和届次 2025年第一次临时股东会 召开日期时间：2025 年 12 月 17 日 14 点 00 分 召开地点：四川省成都市大邑县大安路 98 号成都圣诺生物科技股份有限公 司会议室 （五） 网络投票的系统、起止日期和投票时间。 股东会召开日期：2025年12月17日 本次股东会采用的网络投票系统：上海证券交易所股东会网络投票系统 （二） 股东会召集人：董事会 （三） 投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合 的方式 （四） 现场会议召开的日期、时间和 ...

Group 1 - Enjie Co., Ltd. is planning to acquire 100% equity of Zhongke Hualian and will suspend trading from December 1, 2025 [3] - ST Tianrui's controlling shareholder is planning a change in company control, leading to a trading suspension from December 1, 2025, expected to last no more than two trading days [4] - Jiarong Technology intends to raise no more than 1 billion yuan through a private placement and acquire 100% of Hangzhou Lanran [5] Group 2 - Baillie Gifford's subsidiary received a milestone payment of $250 million related to a collaboration agreement with Bristol-Myers Squibb [6] - Jiangxi Copper is planning to acquire shares of the overseas listed company SolGold Plc, with a non-binding cash offer of 26 pence per share [7][8] - China Shenhua's subsidiary successfully completed a 168-hour trial run of the No. 3 unit of the Beihai Phase II project, which is a key energy development project in Guangxi [9] Group 3 - Huayang Co., Ltd. has launched a high-performance carbon fiber project with an annual production capacity of 200 tons [11] - Dameng Data announced the release of its general manager from detention by the local supervisory committee [12] Group 4 - Zhongwei Company plans to reduce its stake by up to 1% through a block trade [13] - Yulide's board members plan to reduce their holdings by no more than 0.0313% of the company's total shares [14] - Saint Noble Bio's executives plan to reduce their holdings by no more than 0.024% of the company's total shares [15] Group 5 - Aoride plans to sign a comprehensive technical service agreement with a total amount of approximately 635 million yuan [16]

Group 1 - Daqian Ecological announced the resignation of Chairman Zhang Yuan due to personal reasons, affecting his roles in the board and strategic committee [1] - Daqian Ecological, established in October 1988, focuses on urban renewal, rural revitalization, and ecological restoration [1] Group 2 - Haili Biological plans to use up to 500 million yuan of idle funds to invest in financial products issued by banks, brokers, trusts, and fund companies [1] - Haili Biological, founded in July 1981, specializes in in vitro diagnostic reagents and oral tissue repair and regeneration materials [1] Group 3 - Xianglou New Materials' application for a private placement of shares has been accepted by the Shenzhen Stock Exchange [2] - Xianglou New Materials, established in December 2005, is engaged in the research, production, and sales of customized precision stamping new materials [3] Group 4 - Zhuochuang Information has submitted an application for H-share listing to the Hong Kong Stock Exchange [4] - Zhuochuang Information, founded in April 2004, provides market data monitoring, trading price evaluation, industry data analysis, and research [4] Group 5 - Zhongwei Company plans to reduce its shareholding by up to 626,150 shares, representing 1% of the total share capital [5] - Zhongwei Company, established in May 2004, focuses on the research, production, and sales of high-end semiconductor equipment and related products [5] Group 6 - Jiarong Technology intends to raise up to 1 billion yuan through a private placement to acquire 100% of Hangzhou Lanran [6] - Jiarong Technology, founded in February 2005, specializes in membrane separation equipment and high-performance membrane components [6] Group 7 - Dameng Data's director and general manager Pi Yu has had his detention lifted by the local supervisory committee [7] - Dameng Data, established in November 2000, provides various database software, cloud computing, big data products, and related technical services [7] Group 8 - Huayang Co. has launched a 200-ton annual production project for high-performance carbon fiber [8] - Huayang Co., founded in December 1999, is involved in coal production, power generation, and renewable energy technologies [8] Group 9 - Saintno Biological's executives plan to collectively reduce their holdings by up to 37,600 shares, which is 0.024% of the total share capital [9] - Saintno Biological, established in July 2001, focuses on the research, production, and sales of peptide raw materials and formulations [9] Group 10 - *ST Dongyi is in the process of signing a comprehensive technical service agreement worth 635 million yuan [10] - *ST Dongyi, founded in November 1996, provides comprehensive home decoration services [11] Group 11 - Jiangxi Copper is attempting to acquire all shares of London-listed SolGold, with a recent offer of 26 pence per share [12] - Jiangxi Copper, established in January 1997, specializes in copper and gold mining, smelting, and processing [12] Group 12 - China Shenhua's subsidiary has successfully completed a 168-hour trial run of its power generation unit [13] - China Shenhua, founded in November 2004, is involved in coal and electricity production and sales [13] Group 13 - Baile Tianheng's subsidiary has received a milestone payment of 250 million USD from BMS [14] - Baile Tianheng, established in August 2006, focuses on innovative biopharmaceuticals and chemical preparations [14] Group 14 - Yulide's directors plan to reduce their holdings by up to 35,000 shares, representing 0.0313% of the total share capital [15] - Yulide, founded in December 2003, specializes in the research, production, and sales of testing and measuring instruments [15] Group 15 - Aters plans to establish joint ventures with its controlling shareholder to adjust its U.S. market operations [15] - Aters, established in April 2006, focuses on lithium-ion battery separator products and sterile packaging [15] Group 16 - Enjie Co. is planning to acquire 100% of Zhongke Hualian's shares, leading to a stock suspension [16] - Enjie Co., founded in April 2006, specializes in lithium-ion battery separator products and sterile packaging [16] Group 17 - ST Tianrui's controlling shareholder is planning a change in company control, resulting in a stock suspension [16] - ST Tianrui, established in July 2006, focuses on analytical testing instruments and environmental governance [17]

Group 1 - SystImmune, a subsidiary of BaiLi TianHeng, received a milestone payment of $250 million from Bristol-Myers Squibb, with potential future payments totaling up to $2.5 billion and additional payments of up to $7.1 billion based on specific development, registration, and sales milestones [1] - The milestone payment is expected to significantly enhance cash flow and support research and development efforts, serving as a benchmark case for domestic innovative drugs going global [1] Group 2 - Sanofi Biologics announced that two executives plan to reduce their holdings by up to 18,800 shares each, representing 0.012% of the company's total share capital, due to personal financial needs [2] - The combined share reduction is minimal and is not expected to have a significant direct impact on the market, reflecting a common phenomenon in the A-share market [2] Group 3 - Maiwei Biotech's innovative drug 9MW1911 has completed Phase IIa clinical trials in patients with moderate to severe chronic obstructive pulmonary disease (COPD), showing good safety and tolerability across all dosage groups [3] - The annual incidence of acute exacerbations of COPD decreased by over 30% compared to the placebo group at the recommended dose for Phase IIb studies, with a significant reduction in the proportion of patients experiencing severe exacerbations [3] - These results lay a solid foundation for the Phase IIb study, potentially providing new treatment options for the large COPD patient population and showcasing the R&D capabilities and market potential of domestic innovative drugs in respiratory diseases [3] Group 4 - Novartis announced that the FDA has approved Onasemnogene abeparvovec (Itvisma) for treating spinal muscular atrophy (SMA) in patients aged two and older with confirmed SMN1 gene mutations, making it the first and only gene therapy for this broad population [4] - The unique aspect of this drug is its one-time fixed-dose administration, which does not require adjustments based on age or weight, potentially changing the disease progression fundamentally and alleviating the burden of long-term medication [4] Group 5 - Novo Nordisk has submitted a supplemental new drug application to the FDA for a 7.2 mg dose of semaglutide injection, aimed at controlling long-term weight in obese adults in conjunction with a low-calorie diet and increased physical activity [5] - This move is expected to strengthen Novo Nordisk's leading position in the GLP-1 market and provide better treatment options for obese adults [5]

Core Viewpoint - The announcement details a share reduction plan by certain directors and senior management of Chengdu Saintno Biotechnology Co., Ltd. due to personal financial needs, with specific share quantities and timelines outlined for the planned reductions [3][11]. Summary by Sections Shareholding Information - As of the announcement date, Vice General Manager Ma Zhonggang holds 175,616 shares, accounting for 0.1116% of the total share capital, with 156,800 shares held indirectly through an employee stock ownership platform [2]. - Director and Financial Officer Wu Li holds 116,816 shares, representing 0.0742% of the total share capital, with 98,000 shares held indirectly through the same platform [2]. Reduction Plan Details - Ma Zhonggang and Wu Li plan to reduce their holdings by up to 18,816 shares each, which is 0.0120% of the total share capital, within three months after the announcement date [3][6]. - The reduction will occur through centralized bidding or block trading, and the number of shares may be adjusted in case of corporate actions like dividends or stock splits [3][11]. Background of Reducing Parties - The shares intended for reduction originate from stock incentive plans, and the reducing parties do not have any concerted actions with other shareholders [4][5]. Compliance and Commitments - The reducing parties have previously committed to not transferring their shares for a specified period post-IPO, with conditions for extending the lock-up period if certain stock price conditions are met [7][9]. - They are also bound by regulations that limit the amount of shares they can transfer annually and restrict transfers for six months post-employment [8][10].